these - Université de Franche-Comté
these - Université de Franche-Comté these - Université de Franche-Comté
59 Pfenninger J, Aebi C, Bachmann D, Wagner BP. Lung mechanics and gas exchange in ventilated preterm infants during treatment of hyaline membrane disease with multiple doses of artificial surfactant (Exosurf). Pediatr Pulmonol. 1992 Sep;14(1):10-5. 60 Phibbs RH, Ballard RA, Clements JA, Heilbron DC, Phibbs CS, Schuelter MA, Sniderman SH, Tooley WH, Wakeley A. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Pediatrics. 1991 Jul;88(1):1-9. 61 Donn SM. Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome. Expert Opin Investig Drugs. 2005 Mar;14(3):329-34. 62 Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF, Sekar KC, Bernstein G, Keszler M, Visser VE, Merritt TA, Mannino FL, Mastrioianni L, Marcy B, Revak SD, Tsai H, Cochrane GC. A Multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics. 2002;109:1081-87. 63 Cochrane CG, Revak SD Merritt DA, Heldt GP, Hallman M, Cunningham MD, Easa D, Pramanik A, Edwards DK, Alberts MS. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med. 1996 Jan;153(1):404-10. 64 Johansson J, Gustafsson M, Palmblad M, Zaltash S, Robertson B, Curstedt T. Synthetic surfactant protein analogues. Biol Neonate.1998 Sep;74 Suppl 1:9-14. 144
65 Walti H. Natural or artificial surfactants? Arguments in favour of natural surfactants. Arch Pediatr. 1996 Feb;3(2):165-75. 66 Halliday HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs. 1996 Feb;51(2):226-37. 67 Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K and the North American Study Group. A randomized, multicenter, masked comparison trial of poractant alpha (Curosurf) versus Beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol. 2004 Apr;21(3):109-19. 68 Sinha SK, Lacaze-masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agostino R. Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group. A multicenter, randomized, controlled, trial of lucinactant versu poractant alpha among very premature infants at high risk for respiratory distress syndrome. Pediatrics. 2005 Apr;115(4):1030-8. 69 Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, tsai H, Massaro J, d'Agostino R. International Surfaxin Collaborative Study Group. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005 Apr;115(4):1018-29. 145
- Page 116 and 117: Figure 35: mécanisme des lésions
- Page 118 and 119: Mais on peut aussi les séparer en
- Page 120 and 121: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 122 and 123: 2.2. Pharmacologique SDRA : INTERÊ
- Page 124 and 125: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 126 and 127: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 128 and 129: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 130 and 131: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 132 and 133: 3.3. Conclusion sur l’utilisation
- Page 134 and 135: 112
- Page 136 and 137: 114
- Page 138 and 139: 116
- Page 140 and 141: demi-doses : une moitié dans la br
- Page 142 and 143: 120
- Page 144 and 145: la tête et le corps étant inclin
- Page 146 and 147: 124
- Page 148 and 149: 126
- Page 150 and 151: COLLAPSUS : affaissement d’un org
- Page 152 and 153: MALADIE DES MEMBRANES HYALINES : ca
- Page 154 and 155: TRANSSUDAT : liquide organique d’
- Page 156 and 157: 134
- Page 158 and 159: 8 Rooney SA, Young SL, Mendelson CR
- Page 160 and 161: 22 Post M, Batenburg JJ, van Golde
- Page 162 and 163: 34 Ainsworth SB, Milligan DW. Surfa
- Page 164 and 165: 48 Le dictionnaire VIDAL 2005. Pari
- Page 168 and 169: 70 Long W, Corbet A, Cotton R, Cour
- Page 170 and 171: 84 Günther A, Ruppert C, Schmidt R
- Page 172 and 173: 96 Walmrath D, Gunther A, Ghofrani
- Page 174 and 175: 107 Anzueto A, Baughman RP, Guntupa
- Page 176 and 177: 154
- Page 178 and 179: Protéines.........................
- Page 180 and 181: Surfexo® ou Palmitate de colfocér
- Page 182: 160
65 Walti H.<br />
Natural or artificial surfactants? Arguments in favour of natural surfactants. Arch<br />
Pediatr. 1996 Feb;3(2):165-75.<br />
66 Halliday HL.<br />
Natural vs synthetic surfactants in neonatal respiratory distress syndrome.<br />
Drugs. 1996 Feb;51(2):226-37.<br />
67 Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K and the North<br />
American Study Group.<br />
A randomized, multicenter, masked comparison trial of poractant alpha (Curosurf)<br />
versus Beractant (Survanta) in the treatment of respiratory distress syndrome in<br />
preterm infants.<br />
Am J Perinatol. 2004 Apr;21(3):109-19.<br />
68 Sinha SK, Lacaze-masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu<br />
J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agostino R.<br />
Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group. A<br />
multicenter, randomized, controlled, trial of lucinactant versu poractant alpha among<br />
very premature infants at high risk for respiratory distress syndrome.<br />
Pediatrics. 2005 Apr;115(4):1030-8.<br />
69 Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A,<br />
Kornacka MK, Merritt TA, Segal R, Schaber CJ, tsai H, Massaro J, d'Agostino R.<br />
International Surfaxin Collaborative Study Group. A multicenter, randomized,<br />
masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the<br />
prevention of respiratory distress syndrome among very preterm infants.<br />
Pediatrics. 2005 Apr;115(4):1018-29.<br />
145
Change language